Please use this identifier to cite or link to this item:
Title: Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality
Authors: Ren, J
Pang, W
Luo, Y
Cheng, D
Qiu, K
Rao, Y
Zheng, Y
Dong, Y
Peng, J
Hu, Y
Ying, Z
Yu, H
Zeng, X
Zong, Z
Liu, G
Wang, D 
Wang, G
Zhang, W
Xu, W
Zhao, Y
Keywords: Allergic rhinitis
Long-term medications
COVID-19 Testing
Rhinitis, Allergic
Issue Date: 1-Jan-2022
Publisher: Elsevier BV
Citation: Ren, J, Pang, W, Luo, Y, Cheng, D, Qiu, K, Rao, Y, Zheng, Y, Dong, Y, Peng, J, Hu, Y, Ying, Z, Yu, H, Zeng, X, Zong, Z, Liu, G, Wang, D, Wang, G, Zhang, W, Xu, W, Zhao, Y (2022-01-01). Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality. Journal of Allergy and Clinical Immunology: In Practice 10 (1) : 124-133. ScholarBank@NUS Repository.
Abstract: Background: It remains unclear if patients with allergic rhinitis (AR) and/or asthma are susceptible to corona virus disease 2019 (COVID-19) infection, severity, and mortality. Objective: To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19. Methods: Demographic and clinical data of 70,557 adult participants completed SARS-CoV-2 testing between March 16 and December 31, 2020, in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization, and mortality in relation to pre-existing AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality. Results: Patients with AR of all ages had lower positive rates of SARS-CoV-2 tests (relative risk [RR]: 0.75, 95% confidence interval [CI]: 0.69-0.81, P < .001), with lower susceptibility in males (RR: 0.74, 95% CI: 0.65-0.85, P < .001) than females (RR: 0.8, 95% CI: 0.72-0.9, P < .001). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR: 0.93, 95% CI: 0.86-1, P = .044) instead of elderlies. In contrast, patients with asthma tested positively had higher risk of hospitalization (RR: 1.42, 95% CI: 1.32-1.54, P < .001). Neither AR nor asthma had an impact on COVID-19 mortality. None of conventional medications for AR or asthma, for example, antihistamines, corticosteroids, or β2 adrenoceptor agonists, showed association with COVID-19 infection or severity. Conclusion: AR (all ages) and asthma (aged <65) act as protective factors against COVID-19 infection, whereas asthma increases risk for COVID-19 hospitalization. None of the long-term medications had a significant association with infection, severity, and mortality of COVID-19 among patients with AR and/or asthma.
Source Title: Journal of Allergy and Clinical Immunology: In Practice
ISSN: 22132198
DOI: 10.1016/j.jaip.2021.10.049
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality.pdf724.02 kBAdobe PDF


Post-print Available on 01-01-2023


checked on Oct 1, 2022

Page view(s)

checked on Sep 29, 2022


checked on Sep 29, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.